Navigation Links
Stem-cell research: A new genetic switching element
Date:5/22/2014

Slight modifications in their genome sequences play a crucial role in the conversion of pluripotent stem cells into various differentiated cell types. A team at Ludwig-Maximilians-Universitaet (LMU) in Munich has now identified the factor responsible for one class of modification.

Every cell contains stored hereditary information, encoded in the sequence of nucleobases that make up its DNA. However, in any given cell type, only a fraction of this information is actually used. Which genes are activated and which are turned off is in part determined by a second tier of information which is superimposed on the nucleotide sequences that provide the blueprints for protein synthesis. This so-called epigenetic level of control is based on the localized, and in principle reversible, attachment of simple chemical tags to specific nucleotides in the genome. This system plays a major role in the regulation of gene activity, and enables the selective expression of different functions in differentiated cell types.

This explains why such DNA modifications play a major role in the differentiation of stem cells. "Several unusual nucleobases have been found in the genomes of stem cells, which are produced by targeted chemical modification of the known building blocks of DNA. These 'atypical' bases are thought to be important in determining what types of differentiated cells can be derived from a given stem cell line," says Professor Thomas Carell from the Department of Chemistry at LMU. All of the unconventional bases so far discovered are derived from the same standard base cytosine. Furthermore, Carell and his team have shown in earlier work that so-called Tet enzymes are always involved in their synthesis.

Base oxidation regulates gene activity

In cooperation with colleagues at LMU, as well as researchers based in Berlin, Basel and Utrecht, Carell and his group have now shown, for the first time, that a standard base other than cytosine is also modified in embryonic stem cells of mice. Moreover, Tet is at work here too. "During the development of specialized tissues from stem cells, enzymes belonging to the Tet family also oxidize the thymidine base, as we have now shown with the aid of highly sensitive analytical methods based on mass spectrometry. The product of the reaction, hydroxymethyluracil, was previously and as it now turns out, erroneously thought to be synthesized by a different pathway," Carell explains.

The precise function of hydroxymethyluracil remains unclear. However, using an innovative method for the identification of factors capable of binding to and "reading" the chemical tags that characterize unconventional DNA bases, Carell and colleagues have shown that stem cells contain specific proteins that recognize hydroxymethyluracil, and could therefore contribute to the regulation of gene activity in these cells. "We hope that these new insights will make it possible to modulate the differentiation of stem cells causing them to generate cells of a particular type," says Carell. "It would be wonderful if we were one day able to generate whole organs starting from differentiated cells produced, on demand, by stem cell populations."


'/>"/>

Contact: Luise Dirscherl
presse@lmu.de
49-892-180-3243
Ludwig-Maximilians-Universitt Mnchen
Source:Eurekalert

Related biology news :

1. Stem-cell approach shows promise for Duchenne muscular dystrophy
2. Initial research: Mangos effects on ulcerative colitis & bone parameters in animal models
3. Research: Fructose not responsible for increase in non-alcoholic fatty liver disease
4. New research: Effects of eating half an avocado with lunch on satiety & desire to eat between meals
5. Pioneers in Alzheimers research: Research couple honored for its lifetime achievement
6. New research: Wolf Lake ancient forest is endangered ecosystem
7. DoD-funded research: Can climate change heat up conflict?
8. New Research: Modified Citrus Pectin - A Potent Anti-Cancer Therapy
9. PTSD research: Distinct gene activity patterns from childhood abuse
10. Dartmouth research: The clocks are ticking and the climate is changing
11. Influenza research: Can dynamic mapping reveal clues about seasonality?
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/7/2017)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... the LEERINK Partners 6th Annual Global Healthcare Conference at ... 15, 2017 at 10 a.m. Eastern Time. ... accessed at http://wsw.com/webcast/leerink28/zbh .  The webcast will be ... Investor Relations website at http://investor.zimmerbiomet.com . ...
(Date:2/2/2017)... JACKSONVILLE, Fla. , Feb. 2, 2017 /PRNewswire/ ... ), a clinical-stage immuno-oncology company specializing in the ... vaccines for the treatment of cancer and metastatic ... multi-gram scale-up and GMP manufacturing of a second ... T-cell vaccine targeting folate receptor alpha. The manufactured ...
(Date:1/30/2017)... FRANCISCO , Jan. 30, 2017   Invitae ... the fastest growing genetic information companies, today announced that ... financial results and provide 2017 guidance on Monday, February ... conference call that day at 4:45 p.m. Eastern / ... Invitae,s management team will briefly review financial results, guidance, ...
Breaking Biology News(10 mins):
(Date:2/24/2017)... RADNOR, Pa., Feb. 24, 2017  VWR Corporation (NASDAQ: VWR), ... to laboratory and production customers, today reported its financial results ... 2016. Highlights: 4Q16 record ... up 1.0% on an organic basis. ... on an organic basis, while the Americas net sales increased ...
(Date:2/23/2017)... Financial ... data, unaudited)Three Months Ended December 31,Twelve Months Ended December ... $           300$ ... Net Product Revenue 3539(10)%9498(4)%Kuvan Net ... Revenue  756025%297303(2)%Vimizim Net Product Revenue ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced ... for two key immunotherapy technologies from the University ... provides a method to monitor a patient for ... PD-L1 and CTLA-4.  The second license extends the ... patient is likely to have an immune-related adverse ...
(Date:2/23/2017)... Feb. 23, 2017  Imanis Life Sciences announced ... of oncolytic vaccinia viruses for virotherapy research. These ... of Genelux,s proprietary, vaccinia virus-based technology platform for ... enter into a partnership with Genelux to offer ... viruses for use in research," said Dr. ...
Breaking Biology Technology: